14 March 2019
Sofitel Legend Amsterdam The Grand
2018 Presenting Companies
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®.
The Company employs a hybrid business model where it invests directly in its own development programmes as well as collaborating with pharmaceutical partners at all stages of discovery and development. Where there are appropriate opportunities, Ablynx will retain some or all rights to commercialise its products.
Aelin Therapeutics (BEL)
Aelin Therapeutics, founded by VIB, will exploit its proprietary Pept-in™ protein knockdown platform as a novel modality in drug development. The company is based on a very comprehensive preclinical package illustrating different applications of the technology (in bacteria, fungi, viruses, cancer cells).
Affimed engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. Since its Nasdaq-IPO in 2014, Affimed has raised ~$140 million.
Atlas Genetics (UK)
Atlas Genetics is a diagnostics company focused on ultra-rapid (≤ 30 mins) POC molecular tests for infectious diseases and genotyping. The initial commercial focus is on sexually transmitted infections, initially for chlamydia and gonorrhoea, which represents a 67 million tests per year market with well-established regulatory path and reimbursement www.atlasgenetics.com
BioClin Therapeutics (USA)
BioClin is developing a first-in-class anti-FGFR3 antibody (B-701). B-701 was licensed from Genentech and is currently the only targeted biologic specific for FGFR3. BioClin has ongoing clinical studies in metastatic bladder cancer mBC) using multiple therapeutic approaches (as B-701 monotherapy, and in combination therapies with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor).
Cardior Pharmaceuticals (GER)
Cardior is a privately held biopharmaceutical company founded by Prof. Thomas Thum out of the Hannover Medical School. The company is dedicated to becoming world-leader in design, research and development of non-coding RNA-based therapeutics for cardiovascular diseases. Cardior aims to market its products in collaboration with a strategic pharma-partner after clinical validation.
Confo Therapeutics (NL)
Confo Therapeutics is a privately held drug discovery company based in Belgium, supported by a syndicate of specialist investors. Confo is developing a proprietary pipeline of therapeutics which it plans to develop at least until clinical POC. In addition, the Company is entering into revenue-generating discovery partnerships with select pharma.
Curetis is a molecular diagnostics company, which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million.
eTheRNA was founded in January 2013 out of the VUB Laboratory for molecular and cellular therapy. eTheRNA is focused on developing multiple mRNA based immunotherapies to target a broad range of cancer types from its innovative TriMix patent protected platform. TriMix promotes enhanced T-cell immunity against tumour cells.
ERYTECH Pharma (FRA)
Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs.
Evotec AG (GER)
Evotec is a drug discovery company focused on rapidly progressing innovative product approaches with its customers. It operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target identification to IND-enabling studies and high-end CMC (Chemistry, manufacturing and controls). The Company focuses on key therapeutic areas including neuronal diseases, diabetes and diabetic complications, oncology, pain, anti-infectives, respiratory and fibrosis.
For additional information please go to www.evotec.com.
Gadeta B.V. focusses on the development of innovative immunotherapies for cancer. The work of the company is based on the the role of γδ T cell receptors (γδTCRs) in the broad recognition of both hematological and solid tumor cells and their potential use for the treatment of advanced malignancies.
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Galapagos’ pipeline comprises Phase 3 through to discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. Our target discovery platform has delivered three novel mechanisms showing promising patient results in, respectively, inflammatory diseases, idiopathic fibrosis and atopic dermatitis. Galapagos is focused on the development and commercialization of novel medicines that will improve people’s lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 578 employees, operating from its Mechelen, Belgium headquarters and facilities in the Netherlands, France, and Croatia. More information at www.glpg.com.
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab’s technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
Hercules Pharmaceuticals (NL)
Hercules was incorporated in The Netherlands to develop the discoveries of Prof David Sherr from Boston University around cancer treatment based on blocking the Aryl Hydrocarbon Receptor (AhR)
ImCheck Therapeutics is a Marseille-based, privately-held biotech company developing nenext-generationmmuno-modulatory antibodies acting on both adaptive and innate immunity for the treatment of cancer and other immune related diseases.
With a “precision medicine-based” translational approach and several established academic collaborations, ImCheck is uniquely positioned to develop the right therapy for each patient.
Immunic Therapeutics (GER)
Immunic AG is clinical stage biotech company founded in 2016 and focused on the
development of immune modulators two preclinical and clinical stage products to
block Th17 and Th1-mediated immune and autoimmune responses. Immunic, with
headquarters in Planegg-Martinsried near Munich, Germany, is privately held and
supported by several renowned sector investors.
iSTAR Medical, founded in 2011 and headquartered in Wavre, Belgium, is a clinical-stage, medical technology company focused on the development of novel ophthalmic implants for patients with glaucoma. Glaucoma is the second leading cause of adult blindness globally.
iSTAR Medical has exclusive rights to the STAR® material from the University of Washington in Seattle (USA) for ophthalmic use. The porous material exhibits outstanding anti-fibrotic and anti-inflammatory properties providing the foundation for the development of MINIjectTM,
Kiadis Pharma (NL)
Kiadis allodepleted T-cell immunotherapy product can make haploidentical hematopoietic stem cell transplantations safer and more effective. Phase 2 data with lead product ATIR given after HSCT in blood cancer patients shows a clinically relevant improvement over literature for the Baltimore protocol, without risk of severe chronic Graft versus Host Disease.
Medigene is a publicly listed (Frankfurt: MDG1, prime standard, TecDAX) biotechnology company headquartered in Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways
Mint Solutions/MedEye (NL)
MedEye builds tools to help nurses and doctors provide exceptional care for patients. The first product ensures that patients get the right medication at the right time, improving safety, saving lives and reducing the costs of medication errors worldwide.
Modra designs and develops optimized oral formulations of major IV chemotherapies, with an initial focus on taxanes. Modra’s aim is to significantly improve the treatment and quality of life of cancer patients undergoing chemotherapy.
Nouscom is an IO biotech, founded in 2015, operations in Switzerland and Italy, dedicated to development of cancer vaccines. Nouscom raised 54M EUR to date, recent round B lead by Abingworth with participation from new investor 5AM and existing investors Versant Ventures and LSP. Nouscom founders come from Okairos, sold to GSK in 2013.
Oxford Endovascular (UK)
Preventing Brain Haemorrhage
1 in 50 people have brain aneurysms, a disorder where a weak artery wall can rupture into a massive brain bleed. One third of ruptured brain aneurysm patients die and one third of survivors suffer permanent brain damage.
OxThera AB (SWE)
OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal ultra-orphan disease in children, and where there are currently no available therapies. The company has initiated a pivotal Phase III study in PH with Oxabact in order to stop and/or delay disease progression. Oxabact holds orphan drug designations in the EU and the US for the treatment of PH, and in the EU for treatment of Short Bowel Syndrome (SBS).
Probiodrug AG (GER)
Probiodrug AG is a publicly traded (Euronext Amsterdam, PBD) company dedicated to the research and development of new therapeutic products for the treatment of Alzheimer’s disease (“AD”). The company is backed by blue chip institutional investors and lead by an experienced management team with profound track-record in drug research and development, financing and business development.
BPH is an enlargement of the prostate gland, causing difficulty with urination. BPH is one of the most common medical conditions that affects men, and by age 80, it is estimated that 80% of men with suffer from the condition. A spinout of Trinity College Dublin, ProVerum has developed a technology will address the unmet need for urologists to have a treatment option for BPH which can be administered as an office/outpatient based procedure in a matter of minutes, and which is easy and low risk, and very profitable.
Sequana Medical (CH)
Sequana Medical is a commercial stage medtech and an innovator in the management of liver disease, heart failure and other fluid imbalance disorders. Cirrhotic-ascites is a large market and forecast to grow significantly due to the increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
TxCell develops cellular immunotherapies based on regulatory T lymphocytes (Tregs) for autoimmunity, inflammation and transplantation. TxCell develops engineered antigen-specific Tregs, where the antigen specificity is brought by a Chimeric Antigen Receptor (CAR) (CAR-Treg cells). TxCell aims to be the first company worldwide to launch a clinical trial with a CAR-Treg.
Ventaleon is developing inhaled treatments against viral infections. The Company’s lead therapy, is an inhaled LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well-known acetyl salicylic acid (Aspirin®), suitable as an ingredient for inhalable aerosol, has completed Phase II clinical trials to treat severe influenza.
Vivasure Medical (IRE)
Percutaneous large (12F+) arteriotomy closure is an area of unmet clinical need which is growing rapidly, driven by the increased penetration of procedures such as Transcatheter Aortic Valve Repair. Vivasure’s technology enables a fully percutaneous approach for these patients, yielding significant clinical and economic benefits for patients, physicians and payers.
Zealand Pharma (DEN)
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim and a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.